aim
describ
pattern
usag
antivir
treat
influenza
viru
infect
hospit
hong
kong
analyz
central
electron
health
record
includ
dispens
inform
diagnosi
code
inform
collect
admiss
includ
patient
age
sex
admiss
year
month
medic
dispens
match
first
discharg
diagnosi
code
divid
monthli
admiss
episod
relev
popul
denomin
obtain
admiss
rate
stratifi
analys
drug
type
age
group
diagnosi
code
introduct
influenza
viru
infect
caus
consider
morbid
mortal
year
number
antivir
drug
use
treat
influenza
viru
infect
inhibitor
amantadin
rimantadin
use
sinc
respect
although
neither
current
recommend
use
influenza
resist
current
circul
strain
neuraminidas
inhibitor
oseltamivir
zanamivir
approv
us
food
drug
administr
third
neuraminidas
inhibitor
peramivir
approv
although
avail
pandem
emerg
use
author
peramivir
rimantadin
regist
hong
kong
oseltamivir
wide
use
antiinfluenza
drug
global
proven
efficaci
reduc
durat
uncompl
influenza
ill
random
control
trial
observ
studi
indic
benefit
sever
influenza
hong
kong
highli
develop
subtrop
citi
locat
southern
china
popul
million
hong
kong
mix
healthcar
system
approxim
admiss
occur
public
sector
hospit
administ
hospit
author
remaind
occur
privat
hospit
hospit
author
maintain
central
electron
health
record
includ
basic
demograph
inform
summari
encount
healthcar
provid
diagnos
procedur
medic
advers
reaction
allergi
laboratori
result
object
studi
describ
use
influenza
antivir
drug
patient
admit
public
hospit
hong
kong
examin
pattern
usag
compar
influenza
activ
period
obtain
anonym
data
hospit
author
hospit
admiss
antimicrobi
drug
dispens
inform
collect
admiss
includ
patient
age
sex
admiss
year
month
medic
dispens
match
first
discharg
diagnosi
code
use
first
three
digit
intern
classif
diseas
icd
th
edit
analysi
identifi
admit
patient
dispens
five
influenza
antivir
drug
amantadin
oseltamivir
peramivir
rimantadin
zanamivir
determin
whether
admiss
episod
includ
diagnosi
code
influenza
respiratori
diseas
parkinson
diseas
multipl
sclerosi
obtain
popul
denomin
data
age
censu
statist
depart
hong
kong
govern
measur
influenza
activ
hong
kong
use
approach
previou
studi
base
sentinel
surveil
data
weekli
rate
influenzalik
ill
sentinel
privat
gener
practition
centr
health
protect
laboratori
data
weekli
rate
influenza
detect
typesubtyp
among
specimen
submit
public
health
laboratori
servic
branch
centr
health
protect
divid
monthli
admiss
episod
relev
popul
denomin
obtain
admiss
rate
stratifi
analys
drug
type
age
group
diagnosi
code
studi
receiv
ethic
approv
institut
review
board
univers
hong
kong
five
antiinfluenza
antivir
avail
hong
kong
three
regist
studi
period
identifi
oseltamivir
dispens
uniqu
patient
age
group
rate
oseltamivir
higher
postpandem
period
highest
rate
usag
person
occur
februari
peak
larg
epidem
viru
antigen
distinct
compon
vaccin
compon
month
februari
person
hong
kong
admit
hospit
dispens
oseltamivir
year
total
hospit
includ
oseltamivir
treatment
person
children
entir
studi
period
admiss
episod
oseltamivir
dispens
includ
diagnosi
code
influenza
includ
diagnosi
code
respiratori
ill
among
hospit
episod
amantadin
dispens
patient
year
age
male
studi
pattern
use
influenza
antivir
hong
kong
find
oseltamivir
use
increas
consider
pandem
sinc
dispens
approxim
hospit
episod
per
year
notabl
increas
almost
hospit
receiv
oseltamivir
dispens
fig
separ
ecolog
analysi
admiss
data
public
hospit
estim
period
averag
influenzaassoci
respiratori
hospit
per
year
children
older
adult
surveil
studi
comprehens
laboratori
test
two
hospit
hong
kong
estim
influenza
caus
averag
pediatr
year
hospit
per
year
influenza
b
caus
averag
pediatr
hospit
hong
kong
find
suggest
oseltamivir
usag
approxim
estim
occurr
influenzaassoci
respiratori
hospit
older
adult
somewhat
lower
estim
occurr
influenzaassoci
respiratori
hospit
children
one
studi
report
almost
adult
admit
laboratoryconfirm
influenza
teach
hospit
hong
kong
receiv
oseltamivir
treatment
interest
note
oseltamivir
dispens
adult
markedli
greater
influenza
epidem
pandem
consist
much
greater
impact
older
adult
latter
epidem
compar
data
literatur
green
et
al
report
populationbas
data
antivir
dispens
base
insur
record
identifi
similar
drop
amantadin
use
influenza
onward
substanti
use
oseltamivir
pandem
around
dose
dispens
per
popul
outpati
clinic
emerg
room
hospit
studi
estim
oseltamivir
dispens
hong
kong
popul
inpati
pandem
larg
studi
hospit
laboratoryconfirm
influenza
countri
worldwid
muthuri
et
al
report
receiv
oseltamivir
studi
site
provid
data
may
repres
broader
health
system
countri
use
oseltamivir
hospit
given
continu
resist
circul
influenza
strain
inhibitor
amantadin
mainli
use
treat
parkinson
diseas
sinc
similar
find
green
et
al
although
unlik
green
et
al
find
evid
amantadin
use
multipl
sclerosi
concern
resist
oseltamivir
reemerg
larg
scale
season
virus
antivir
avail
peramivir
use
hong
kong
low
level
compar
oseltamivir
yet
local
regist
howev
oseltamivir
peramivir
may
share
resist
pattern
would
advantag
increas
zanamivir
usag
consid
licens
laninamivir
consid
antivir
therapeut
develop
interpret
find
note
oseltamivir
use
would
patient
influenza
viru
infect
laboratoryconfirm
influenza
viru
infect
case
may
use
prophylaxi
initi
patient
within
hour
contact
infect
individu
laboratori
result
avail
empir
treatment
patient
influenzalik
ill
period
increas
influenza
activ
found
oseltamivir
usag
increas
consider
follow
pandem
sinc
appear
track
pattern
influenza
activ
close
fig
clear
oseltamivir
use
increas
onward
amantadin
longer
recommend
use
influenza
unclear
increas
amantadin
use
notabl
adult
older
adult
fig
knowledg
amantadin
frequent
use
treat
patient
sar
possibl
increas
attent
pneumonia
increas
laboratori
test
sar
outbreak
led
greater
identif
influenza
viru
infect
treat
amantadin
studi
number
limit
first
detail
patient
data
unabl
link
dispens
antivir
symptom
laboratori
test
data
although
match
first
discharg
code
previou
work
use
data
hospit
author
demonstr
reason
high
code
accuraci
studi
attain
diagnost
record
respiratori
ill
within
first
discharg
code
consid
reason
inde
difficulti
valid
diagnost
code
report
other
discharg
code
may
alway
reflect
true
caus
admiss
may
misclassifi
reason
antivir
use
patient
second
studi
includ
public
hospit
cover
admiss
probabl
greater
fraction
acut
admiss
studi
includ
antivir
use
outpati
set
therefor
estim
underestim
total
use
antivir
hong
kong
howev
unlik
underascertain
antivir
use
public
hospit
prescript
dispens
manag
electron
system
access
third
examin
usag
medic
antipyret
steroid
studi
final
suffici
inform
number
dose
time
medic
clinic
outcom
draw
infer
effect
antivir
treatment
studi
conclus
studi
demonstr
valu
use
electron
hospit
record
analyz
medic
use
identifi
consider
oseltamivir
use
year
among
inpati
hong
kong
